Loading stock data…
$0.86+0.02 (+2.36%)
Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. in the Healthcare sector is trading at $0.86 with a market capitalization of $6M. Wall Street consensus targets $4.00 (1 analysts), implying a +365.1% move over the next 12 months. The stock is currently near its 52-week low of $0.84, remaining 38.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.01M↓ | -$1.93M↓ | -$1.90M↓ | -$1.76M↑ | -$1.77M |
| Net Income | -$2.97M↓ | -$1.85M↑ | -$1.86M↓ | -$1.69M↑ | -$1.70M |
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment pro...